CVRx names John Landry from Nyxoah as next CFO

CVRx's board appointed John Landry as chief financial officer on September 21, 2026. Landry, currently CFO of Nyxoah and formerly a senior finance leader at Vapotherm and other medical device firms, joins CVRx on October 12, 2026 and assumes the CFO role after the company files its third-quarter Form 10-Q. He brings more than two decades of medical device and public company finance experience. The package includes a $500,000 base salary plus cash incentive and equity awards. Jared Oasheim, who led CVRx through its IPO, will stay for a transition period. CVRx commercializes Barostim, an implantable neuromodulation device for heart failure. On the announcement day the stock closed at $2.970, down 2.30%. The most recent analyst rating is Buy with a $5.00 price target. Landry's October 12 start and the handoff after the quarterly filing are the next steps.